Last Updated: November 8, 2026

HYDROCORTONE Drug Patent Profile

« Back to Dashboard


Which patents cover Hydrocortone, and when can generic versions of Hydrocortone launch?

Hydrocortone is a drug marketed by Merck and is included in four NDAs.

The generic ingredient in HYDROCORTONE is hydrocortisone. There are three drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the hydrocortisone profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Hydrocortone

A generic version of HYDROCORTONE was approved as hydrocortisone by IMPAX LABS INC on March 30th, 2007.

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for HYDROCORTONE?
  • What are the global sales for HYDROCORTONE?
  • What is Average Wholesale Price for HYDROCORTONE?
Summary for HYDROCORTONE
US Patents:0
Applicants:1
NDAs:4
Raw Ingredient (Bulk) Api Vendors: 109
Clinical Trials: 13
DailyMed Link:HYDROCORTONE at DailyMed
Recent Clinical Trials for HYDROCORTONE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Cancer Institute (NCI)Phase 1
Children's Oncology GroupPhase 1
EsPhALL network I-BFM Study GroupPhase 3

See all HYDROCORTONE clinical trials

US Patents and Regulatory Information for HYDROCORTONE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck HYDROCORTONE hydrocortisone acetate INJECTABLE;INJECTION 008228-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Merck HYDROCORTONE hydrocortisone acetate OINTMENT;OPHTHALMIC, OTIC 009018-003 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Merck HYDROCORTONE hydrocortisone acetate INJECTABLE;INJECTION 008228-004 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Merck HYDROCORTONE hydrocortisone sodium phosphate INJECTABLE;INJECTION 012052-001 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Merck HYDROCORTONE hydrocortisone TABLET;ORAL 008506-011 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Merck HYDROCORTONE hydrocortisone TABLET;ORAL 008506-007 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for HYDROCORTONE

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Takeda Pharmaceuticals International AG Ireland Branch Plenadren hydrocortisone EMEA/H/C/002185Treatment of adrenal insufficiency in adults. Authorised no no no 2011-11-03
Diurnal Europe B.V. Alkindi hydrocortisone EMEA/H/C/004416Replacement therapy of adrenal insufficiency in infants, children and adolescents (from birth to < 18 years old). Authorised no no no 2018-02-09
Diurnal Europe B.V. Efmody hydrocortisone EMEA/H/C/005105Treatment of congenital adrenal hyperplasia (CAH) in adolescents aged 12 years and over and adults. Authorised no no no 2021-05-27
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.